Equillium Surpasses Interim Enrollment Target For Phase 3 EQUATOR Study Of Itolizumab II Acute Graft-Versus-Host Disease
Equillium Surpasses Interim Enrollment Target For Phase 3 EQUATOR Study Of Itolizumab II Acute Graft-Versus-Host Disease
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.